aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

aTyr Pharma, Inc.NASDAQ: ATYR

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $11.04M fell 30.0% year over year, behind the -7.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 25.4% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.

Context

  • Operating expenses amounted to 40138.9% of revenue in FY2025, up 11139.4 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.0% toward the trailing-twelve-month pace of -7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.04M-25.4% QoQ
Last fiscal yearDec 2025
$76.26M+11.9% YoY
LTMMar 2026
$50.96M-7.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.0%——
1 year+11.9%——
3-year CAGR+11.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
76.26M USD
Year-over-year change
+11.9%
4-year CAGR
+23.6%

Operating Expenses vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.1% is the 4th highest of 8, against a peer median of -10.8%.
  • Operating expenses amounts to 26818.9% of revenue for ATYR, versus a peer median of 183.7%.
ATYR Competitors
Operating Expenses for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALXOALX Oncology Holdings Inc.LTM Mar 2026$91.02M USD-33.2%-6.5%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$82.81M USD-13.0%-1.4%183.7%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$82.58M USD-10.8%+36.3%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$60.34M USD-23.7%-28.4%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$55.03M USD+0.4%—1398.8%
ATYRaTyr Pharma, Inc.LTM Mar 2026$50.96M USD-7.1%+11.4%26818.9%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$29.76M USD-3.7%+15.1%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$23.06M CAD-5.4%-2.4%125.6%
Peer median (excluding ATYR) —-10.8%-1.9%183.7%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.